Informations générales (source: ClinicalTrials.gov)
Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization (BioNéoRet)
Observational
Institut National de la Santé Et de la Recherche Médicale, France (Voir sur ClinicalTrials)
juillet 2020
juillet 2027
29 avril 2025
The aim of the study is to find biomarkers in the blood and aqueous humor of patients
with type 1 choroidal neovascularization and correlate them with the response to
anti-VEGF treatment.
Etablissements
Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
HOPITAL FOCH | Francine BEHAR-COHEN | 05/05/2025 07:12:07 | Contacter | ||
Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
AP-HP - Hôpital Cochin | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
Patients of group 1:
- Patients with type 1 choroidal neovascularization in a context of central serous
chorioretinoathy or age related macular degeneration
- Patients without intravitreal injection or last intravitreal injection > 3 months
- Informed signed consent
Patients of group 2:
- Patients without choroidal neovascularization
- Patients with intraocular surgery (cataract or vitrectomy surgery)
- Signed consent
Patients of group 1:
- Patients with type 1 choroidal neovascularization in a context of central serous
chorioretinoathy or age related macular degeneration
- Patients without intravitreal injection or last intravitreal injection > 3 months
- Informed signed consent
Patients of group 2:
- Patients without choroidal neovascularization
- Patients with intraocular surgery (cataract or vitrectomy surgery)
- Signed consent
- Myocardial infarction < 12 months
- Chronic renal failure
- Inflammatory disease
- Infectious disease :HIV, viral hepatitis, tuberculosis
- Type 1 or 2 Diabetes
- Patients treated by mineralocorticoid antagonist treatment.
- Type 2 or 3 choroidal neovascularization
- Pregnant woman